- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
- 1 big thing: Congress takes on PBMs
- Here comes Humira competition
- Humira Competitors Don’t Guarantee Lower Patient Drug Costs
- The State of Biosimilars: What to Watch
- ‘The Price of Business’: Discussing the Latest Inflation Report
- Alex Brill Interviewed on the Future of the Adalimumab Market
- Taking Stock of the Humira Biosimilars Market
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
- Analyzing the Build It in America Act: Proposals for Business Tax Reform
